surmount-osa trial tirzepatide results Entering a New Era in Sleep-Apnea Treatment Terzapatid in Managing OSA
Description
doi: 10.1001/jama.2024.9217 31 MoizALevettJYFilionKBPeriKReynierPEisenbergMJ
In vitro, tirzepatide regulated oxidative stress and the PI3K-AKT pathway in high glucose-exposed podocytes, with its antioxidative effects reversed by a PI3K inhibitor
Known serious hypersensitivity to tirzepatide or any of the excipients
Individual responses range from 15 to 30 percent weight loss, with higher responders typically being those who implement comprehensive lifestyle modifications alongside medication use
